Benzinga · Feb 25, 2026
EN
NASDAQ · ENVB
Enveric Biosciences, Inc.
Healthcare · Biotechnology
$1.59
Up+$0.10 (+6.71%)
Updated Sep 18, 2026, 6:07 AM
SID Score
3.6/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 3.25M
- P/E ratio
- -0.12
- Dividend yield
- 0.00%
- 52-week range
- $1.17 – $13.25
- Volume
- 172.69K
- Avg. volume
- 85.35K
Price performance
ENVB price history
1M range · 20 trading sessions · Daily adjusted prices
ENVB closed at $1.59 after 20 trading sessions, up 14.39% for the selected period.
- Last close
- $1.59
- Period change
- +14.39%
- Period low
- $1.37
- Period high
- $1.59
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 17, 2026 | $1.4933 | $1.64 | $1.4892 | $1.59 | 172.69K |
| Sep 16, 2026 | $1.45 | $1.54 | $1.45 | $1.49 | 52.12K |
| Sep 15, 2026 | $1.47 | $1.53 | $1.44 | $1.46 | 75.32K |
| Sep 14, 2026 | $1.4231 | $1.5378 | $1.4098 | $1.48 | 104.93K |
| Sep 11, 2026 | $1.45 | $1.48 | $1.42 | $1.42 | 38.75K |
| Sep 10, 2026 | $1.45 | $1.46 | $1.42 | $1.46 | 11.47K |
| Sep 9, 2026 | $1.48 | $1.48 | $1.40 | $1.455 | 29.79K |
| Sep 8, 2026 | $1.38 | $1.4515 | $1.38 | $1.42 | 51.55K |
| Sep 4, 2026 | $1.40 | $1.45 | $1.36 | $1.39 | 56.74K |
| Sep 3, 2026 | $1.47 | $1.47 | $1.3737 | $1.44 | 42.96K |
| Sep 2, 2026 | $1.40 | $1.44 | $1.37 | $1.44 | 21.28K |
| Sep 1, 2026 | $1.39 | $1.39 | $1.35 | $1.37 | 20.99K |
| Aug 31, 2026 | $1.35 | $1.38 | $1.33 | $1.37 | 38.53K |
| Aug 28, 2026 | $1.41 | $1.41 | $1.34 | $1.37 | 22.21K |
| Aug 27, 2026 | $1.371 | $1.39 | $1.34 | $1.37 | 36.7K |
| Aug 26, 2026 | $1.47 | $1.52 | $1.1701 | $1.37 | 403.14K |
| Aug 25, 2026 | $1.44 | $1.49 | $1.3985 | $1.46 | 64.79K |
| Aug 24, 2026 | $1.44 | $1.4709 | $1.37 | $1.41 | 58.2K |
| Aug 21, 2026 | $1.40 | $1.44 | $1.38 | $1.43 | 89.15K |
| Aug 20, 2026 | $1.34 | $1.39 | $1.29 | $1.39 | 132.77K |
Latest ENVB news
The latest Smart Investors Daily articles mentioning ENVB.
Stock researchCompany · Overview
ENVB research
Overview
Company profile and research snapshot.
Company profile
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Mar 6, 2025 | HC Wainwright & Co. | Buy | — |
| Jan 30, 2024 | HC Wainwright & Co. | Buy | — |
| Jun 1, 2022 | Alliance Global Partners | Buy | — |
| Mar 8, 2022 | Aegis Capital | Hold | — |
| Jul 8, 2021 | Aegis Capital | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Feb 25, 2026
Gilgamesh Withdraws Patent Fight Against Enveric After $1.2 Billion AbbVie Deal, CEO Says Key Drug Claims Now Uncontested
Gilgamesh withdraws patent challenge against Enveric, leaving the key psilocybin patent uncontested.
Benzinga · Feb 25, 2026
Enveric Biosciences Announces Withdrawal Of Petition Against Patent; Co Says There Are 'No Remaining Challenges' Pending Against Patent
Benzinga · Feb 19, 2026
Enveric Biosciences shares are trading higher after the company announced new mechanistic data demonstrating that its lead candidate, EB-003, activates both Gq- and β-arrestin–mediated signaling downstream of the 5-HT₂A receptor.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
